Abstract
Objective
To determine the incidence of rash in HIV-1 infected individuals starting a nevirapine-containing regimen in an unselected outpatient clinic population. Possible risk factors including plasma concentrations of nevirapine were evaluated for their relationship with the occurrence of a rash.
Methods
The occurrence of rash was extracted from the outpatient medical records or based on a prescription of the antihistaminic cetirizine as documented by the community pharmacy within the first 90 days of nevirapine use. During regular visits to the clinic blood samples were collected for the determination of nevirapine plasma concentrations. Possible risk factors such as demographics, immunology, virology, clinical chemistry and antiretroviral pretreatment were collected at baseline for each patient. In addition, concomitantly used drugs during the nevirapine-based regimen were recorded. The association between these factors and the occurrence of rash was studied. Primary outcome was the onset of rash within the first 90 days after initiation of a nevirapine-containing regimen.
Results
Data from 216 HIV-1-infected patients were used in this study. Thirty-eight patients (17.6%) developed a rash of some grade that led to discontinuation of nevirapine in seven patients (3.2% of the included patients). The median time to occurrence of rash was 26 days (interquartile range 17–46 days). The multivariate analysis showed that patients pretreated with antiretroviral drugs less than 12 months before the initiation of a nevirapine-containing regimen had a more than 2.5-fold increased risk of developing rash. Furthermore, nevirapine plasma concentrations were also significantly related to the occurrence of rash. A more than twofold increased risk for developing rash was observed for patients with nevirapine plasma concentrations above 5.3 mg/l.
Conclusions
This is the first study demonstrating that patients with antiretroviral pretreatment less than 12 months and with nevirapine plasma concentrations above 5.3 mg/l during the first 90 days of treatment are at a higher risk for the development of rash. It is therefore advised to monitor this group of patients carefully when initiating nevirapine-containing therapy.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Coopman SA, Johnson RA, Platt R, Stern RS (1993) Cutaneous disease and drug reactions in HIV infection. N Engl J Med 328:1670–1674
Uthayakumar S, Nandwani R, Drinkwater T, Nayagam AT, Darley CR (1997) The prevalence of skin disease in HIV infection and its relationship to the degree of immunosuppression. Br J Dermatol 137:595–598
Carr A, Cooper DA (2000) Adverse effects of antiretroviral therapy. Lancet 356:1423–1430
Fagot J-P, Mockenhaupt M, Bouwes-Bavinck J-N, Naldi L, Viboud C, Roujeau J-C for the EuroSCAR Study Group (2001) Nevirapine and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. AIDS 15:1843–1848
Warren KJ, Boxwell DE, Kim NY, Drolet BA (1998) Nevirapine-associated Stevens-Johnson syndrome. Lancet 351:567
Havlir D, Cheeseman SH, McLaughlin M, Murphy R, Erice A, Spector SA et al (1995) High-dose nevirapine: safety, pharmacokinetics, and antiviral effect in patients with human immunodeficiency virus infection. J Infect Dis 171:537–545
Cheeseman SH, Hattox SE, McLaughlin MM, Koup RA, Andrews C, Bova CA et al (1993) Pharmacokinetics of nevirapine: initial single-rising-dose study in humans. Antimicrob Agents Chemother 37:178–182
Riska P, Lamson M, MacGregor T, Sabo J, Hattox S, Pav J et al (1999) Disposition and biotransformation of the antiretroviral drug nevirapine in humans. Drug Metab Dispos 8:895–901
De Jong MD, Vella S, Carr A, Boucher AB, Imrie A, French M et al (1997) High-dose nevirapine in previously untreated human immunodeficiency virus type 1-infected persons does not result in sustained suppression of viral replication. J Infect Dis 175:966–970
Montaner JSG, Reiss P, Cooper D, Vella S, Harris M, Conway B et al (1998) A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients. JAMA 279:930–937
D'Aquila RT, Hughes MD, Johnson VA, Fischl MA, Sommadossi J-P, Liou S et al (1996) Nevirapine, zidovudine, didanosine compared with zidovudine and didanosine in patients with HIV-1 infction. Ann Intern Med 124:1019–1030
Floridia M, Bucciardini R, Ricciardulli D, Fragola V, Pirillo MF, Weimer LE et al (1999) A randomized, double-blind trial on the use of a triple combination including nevirapine, a nonnucleoside reverse transcriptase HIV inhibitor, in antiretroviral-naive patients with advanced disease. JAIDS 20:11–19
Carr A, Vella S, de Jong MD, Sorice F, Imrie A, Boucher CA et al (1996) A controlled trial of nevirapine plus zidovudine versus zidovudine alone in p24 antigenaemic HIV-infected patients. AIDS 10:635–641
Barreiro P, Soriano V, Casas E, Estrada V, Téllez MJ, Hoetelmans R et al (2000) Prevention of nevirapine-associated exanthema using slow-dose escalation and/or corticosteroids. AIDS 14:2153–2157
Wit FWNM, Wood R, Horban A, Beniowski M, Schmidt RE, Gray G et al (2001) Prednisolone does not prevent hypersensitivity reactions in antiretroviral drug regimens containing abacavir with or without nevirapine. AIDS 15:2423–2429
Antinori A, Baldini F, Girardi E, Cingolani A, Zaccarelli M, Di Giambenedetto S et al (2001) Female sex and the use of anti-allergic agents increase the risk of developing cutaneous rash associated with nevirapine therapy. AIDS 15:1579–1581
Knobel H, Miro JM, Domingo P, Rivero A, Márquez M, Force L et al (2001) Failure of a short-term prednisone regimen to prevent nevirapine-associated rash: a double-blind placebo-controlled: the GESIDA 09/99 study. JAIDS 28:14–18
Lee WM (1997) Hepatitis B virus infection. N Engl J Med 337:1733–1745
Sharara AI, Hunt CM, Hamilton JD (1996) Hepatitis C. Ann Intern Med 125:658–668
Heeswijk, RPG van, Hoetelmans RMW, Meenhorst PL, Mulder JW, Beijnen JH (1998) Rapid determination of nevirapine in human plasma by ion-pair reversed phase high-performance liquid chromatography with ultraviolet detection. J Chromatogr B Biomed Appl 713:395–399
De Maat, MMR, Huitema ADR, Mulder JW, Meenhorst PL, Van Gorp ECM, Beijnen JH (2002) Population pharmacokinetics of nevirapine in an unselected cohort of HIV-1-infected individuals. Br J Clin Pharmacol 53:552
Bersoff-Matcha SJ, Miller WC, Aberg JA, Van der Horst C, Hamrick HJ, Powderly WG et al (2001) Sex differences in nevirapine rash. Clin Infect Dis 32:124–129
Wit FWNM, for the Dutch HIV-Treating Physicians (2000) Experience with nevirapine in previously treated HIV-1-infected individuals. Antivir Ther 5:257–266
Derisi M, Ballard C, Abulhosn K, Colwell B, Barber E, Mathews WC (2000) Sulfa-associated rash and race are risk factors for non-nucleoside reverse transcriptase inhibitor (NNRTI)-associated rash. 7th Conference on Retroviruses and Opportunistic Infections, San Francisco, 31 January–2 February, abstract 61
Barreiro P, Soriano V, González-Lahoz J (2001) Prevention of nevirapine-associated rash. Lancet 357:392
Acknowledgements
The authors thank ZAO Health Insurances, Amsterdam, The Netherlands for financial support. Hanneke Paap is kindly acknowledged for her help with the collection of data.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
de Maat, M.M.R., ter Heine, R., Mulder, J.W. et al. Incidence and risk factors for nevirapine-associated rash. Eur J Clin Pharmacol 59, 457–462 (2003). https://doi.org/10.1007/s00228-003-0613-3
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00228-003-0613-3